康臣药业(01681)公布2023年业绩权益股东应占溢利为7.845亿元同比增加约14.9% 末期息每股0.3港元

智通财经03-28

智通财经APP讯，康臣药业(01681)公布2023年业绩，收入为人民币25.9亿元，同比增加约10.7%。权益股东应占溢利为人民币7.845亿元，同比增加约14.9%。每股基本盈利0.99元，拟派末期股息每股0.3港元。其中，肾科药物的销售收入于2023年约为人民币17.4亿元，较上年同比增长约11.0%。集团龙头产品尿毒清颗粒继续保持稳健增长，实现销售收入约人民币16.5亿元，较上年同比...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422185021?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-28 12:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422185021","market":"hk","top_or_hot":-1,"title":"康臣药业(01681)公布2023年业绩 权益股东应占溢利为7.845亿元 同比增加约14.9% 末期息每股0.3港元","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康臣药业(01681)公布2023年业绩，收入为人民币25.9亿元，同比增加约10.7%。 权益股东应占溢利为人民币7.845亿元，同比增加约14.9%。 每股基本盈利0.99元，拟派末期股息每股0.3港元。其中，肾科药物的销售收入于2023年约为人民币17.4亿元，较上年同比增长约11.0%。集团龙头产品尿毒清颗粒继续保持稳健增长，实现销售收入约人民币16.5亿元，较上年同比...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1094464.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康臣药业(01681)公布2023年业绩 权益股东应占溢利为7.845亿元 同比增加约14.9% 末期息每股0.3港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康臣药业(01681)公布2023年业绩 权益股东应占溢利为7.845亿元 同比增加约14.9% 末期息每股0.3港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-28 12:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1094464.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康臣药业(01681)公布2023年业绩，收入为人民币25.9亿元，同比增加约10.7%。 权益股东应占溢利为人民币7.845亿元，同比增加约14.9%。 每股基本盈利0.99元，拟派末期股息每股0.3港元。其中，肾科药物的销售收入于2023年约为人民币17.4亿元，较上年同比增长约11.0%。集团龙头产品尿毒清颗粒继续保持稳健增长，实现销售收入约人民币16.5亿元，较上年同比...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1094464.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01681","symbol_name":"康臣药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1094464.html","article_id":"2422185021","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422185021","pubTimestamp":1711598726,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康臣药业 公布2023年业绩，收入为人民币25.9亿元，同比增加约10.7%。权益股东应占溢利为人民币7.845亿元，同比增加约14.9%。每股基本盈利0.99元，拟派末期股息每股0.3港元。其中，肾科药物的销售收入于2023年约为人民币17.4亿元，较上年同比增长约11.0%。集团龙头产品尿毒清颗粒继续保持稳健增长，实现销售收入约人民币16.5亿元，较上年同比增长约10.2%，稳居肾病口服现代中成药品类领先地位。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01681":"康臣药业","BK1191":"制药","BK1606":"中医药概念"},"translate_title":"Kangchen Pharmaceutical (01681) announced its 2023 results. The profit attributable to equity shareholders was 784.5 million yuan, an increase of about 14.9% year-on-year. The final interest rate was 0.3 Hong Kong dollars per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":1},"content_text":"智通财经APP讯，康臣药业(01681)公布2023年业绩，收入为人民币25.9亿元，同比增加约10.7%。 权益股东应占溢利为人民币7.845亿元，同比增加约14.9%。 每股基本盈利0.99元，拟派末期股息每股0.3港元。其中，肾科药物的销售收入于2023年约为人民币17.4亿元，较上年同比增长约11.0%。集团龙头产品尿毒清颗粒继续保持稳健增长，实现销售收入约人民币16.5亿元，较上年同比增长约10.2%，稳居肾病口服现代中成药品类领先地位。医用成像对比剂的销售收入于2023年约为人民币15.6亿元，较上年同比略为减少4.6%。于2023年12月，碘帕醇注射液一致性评价获批通过，钆喷酸葡胺注射液一致性评价也正等候审批结果，多个在研影像产品进展顺利，有望为集团影像产品线发展带来新动力。妇儿系列产品表现亮眼，销售增长约22.7%，成为集团收入贡献第二大板块。公告称，整体销售收入的增长主要是由于集团持续致力开拓产品市场以及发展全国各地的销售网络所致。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422185021"}

康臣药业(01681)公布2023年业绩 权益股东应占溢利为7.845亿元 同比增加约14.9% 末期息每股0.3港元

精彩评论

康臣药业(01681)公布2023年业绩权益股东应占溢利为7.845亿元同比增加约14.9% 末期息每股0.3港元